RupeestopAbout UsNewsletter

Compiled by Rupeestop LLP, SEBI RIA INA000022701. NAV as on 18 Aug 2026. Factsheet Jun 2026. About · Disclosures

HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment

HDFC Mutual Fund
Sectoral Pharma and HealthcareDirectIDCW
NAV

₹22.3

As on 18 Aug 2026

Vs category

PeriodThis fundCategoryRank
1 year+25.46%
3 year+32.38%
5 year+32.38%

All Sectoral Pharma and Healthcare funds · HDFC Mutual Fund

Returns

From NAVs through 18 Aug 2026

1Y
+25.46%
Total
3Y
+32.38%
p.a.
5Y
+32.38%
p.a.
SI
+32.38%
p.a.

Calendar years

+13.96%
2023
+52.22%
2024
+2.42%
2025
+25.96%
2026 YTD

Rolling 1-year · 22 overlapping windows

+4.21%avg +23.60%+63.98%

Fund facts

Fund details from the Jun 2026 factsheet

Fund size
₹2362.44 Cr
Expense ratio
0.92%
Exit load
None
Lock-in
None
Launched03 Oct 2023
StructureOpen Ended
ISININF179KC1HP8

Where the money is invested

Split by asset type.

By asset type

Equity98.70%
Cash1.30%

What the fund holds

35 holdings · portfolio as on 30 May 2026

  • Sun Pharmaceuticals Industries Ltd
    Healthcare
    9.2%
  • Divi's Laboratories Ltd
    Healthcare
    8.02%
  • Lupin Ltd
    Healthcare
    5.45%
  • Max Healthcare Institute Ltd Ordinary Shares
    Healthcare
    5.26%
  • Aster DM Healthcare Ltd Ordinary Shares
    Healthcare
    5.18%
  • Cipla Ltd
    Healthcare
    4.92%
  • Acutaas Chemicals Ltd
    Basic Materials
    4.5%
  • Alkem Laboratories Ltd
    Healthcare
    4.36%
  • Anthem Biosciences Ltd
    Healthcare
    4.15%
  • Ipca Laboratories Ltd
    Healthcare
    3.5%

Concentration

Top 5 weight
33.12%
Top 10 weight
54.55%
Avg turnover
43.33%

Risk and quality measures

How steady the returns have been.

Return quality

Sharpe
1
Better than category avg 0.48
Alpha
9.59
Return above the benchmark

Risk

Std deviation
16.31%
How much returns swing
Beta
1.04
Below category avg 0.94
R-squared
97.1%
How closely it tracks the benchmark

Who manages this fund

2 fund managers

  • NM
    Nikhil Mathur
    2.5 years in the industry
    Runs 1 scheme
  • DM
    Dhruv Muchhal
    2.7 years in the industry
    Runs 46 schemes

Other versions

  • regularGrowth
    HDFC Pharma and Healthcare Fund Regular Plan Growth
    NAV ₹17.38
  • regularIDCW
    HDFC Pharma and Healthcare Fund Regular Plan IDCW Reinvestment
    NAV ₹17.38
  • directGrowth
    HDFC Pharma and Healthcare Fund Direct Plan Growth
    NAV ₹17.82
  • directIDCW
    HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment
    NAV ₹17.82

FAQ

What is HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment NAV today?

The latest NAV of HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment is ₹22.3 as on 18 Aug 2026.

How has HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment performed vs its category?

1-year return +25.46%. Past performance does not guarantee future returns.

What are the returns of HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment?

Trailing returns from published NAVs: 1 year +25.46%, 3 year +32.38% a year, 5 year +32.38% a year, since our first NAV +32.38% a year. Past performance does not guarantee future returns.

How would a SIP in HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment have been illustrated?

The SIP illustration on this page uses ₹5,000 a month for 10 years at this fund's 3-year annualised return of +32.38%. It is not a forecast.

What is the expense ratio and fund size of HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment?

For HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment, the expense ratio is 0.92% and fund size (AUM) is ₹2362.44 Cr.

What is the ISIN of HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment?

The ISIN for HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment is INF179KC1HP8.

Mutual fund investments are subject to market risks. Read all scheme related documents carefully before investing. Past performance does not guarantee future returns and is not an indicator of future results.

Figures on this page come from published NAVs and the scheme's monthly factsheet. They are for information only and are not investment advice or a recommendation to buy or sell any scheme.